CompletedPhase 4

Treatments for Psychogenic Nonepileptic Seizures (NES)

United States38 participantsStarted 2003-12

Plain-language summary

The investigators propose that treatment of the comorbid disorders (depression, anxiety, and impulsivity) with sertraline in patients with lone psychogenic nonepileptic seizures (NES), will result in a decreased number of NES. The purpose of this study is to provide pilot testing and data to inform the future randomized controlled trial based on the hypothesis.

Who can participate

Age range18 Years – 95 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Video electroencephalogram (vEEG) confirmed diagnosis of NES * Have at least one nonepileptic seizure per month * Comorbid diagnosis of either depression, anxiety, or post traumatic stress disorder (PTSD) * Able to complete self report symptom scales * Not receiving optimized antidepressant medication Exclusion Criteria: * Equivocal electroencephalogram (EEG) findings * Current suicidality, litigation, or self-mutilation * Using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan * Allergy/sensitivity to sertraline * Current alcohol/drug dependence * Serious medical illness requiring current hospitalization

What they're measuring

Number of Nonepileptic Seizures (NES)

Timeframe: bi-weekly at baseline and weeks 2, 4, 6, 8, 10, 12

Trial details

NCT IDNCT00159965

SponsorRhode Island Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-06

Results submitted2010-08-11

View on ClinicalTrials.gov More Convulsion, Non-Epileptic trials